Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

News

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Jun 1, 2020 10:30 am EDT Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
Apr 7, 2020 8:00 am EDT Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
rss_feed News RSS
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement